Print this page
immunotherapy
-
A Phase 2 Study of Blinatumomab in Combination with Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged < 1 to < 31 Years Old with First Relapse.
Protocol: 112011Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site -
A Phase 2 Study of Blinatumomab in Combination with Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged < 1 to < 31 Years Old with First Relapse.
Protocol: 112011Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site -
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
Protocol: 112106Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Kidney -
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
Protocol: 112106Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Kidney -
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma.
Protocol: 112404Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma.
Protocol: 112404Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC).
Protocol: 112405Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC).
Protocol: 112405Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis.
Protocol: 112506Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Other Hematopoietic -
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis.
Protocol: 112506Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Other Hematopoietic -
An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia.
Protocol: 112510Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Leukemia, other -
An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia.
Protocol: 112510Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Leukemia, other -
Moviendo las Caderas: Effects of Latin Dancing on Sleep Quality in Hispanic Cancer Survivors.
Protocol: 132420Principal Investigator:
- Evelyn Arana
Applicable Disease Sites: Any Site -
Moviendo las Caderas: Effects of Latin Dancing on Sleep Quality in Hispanic Cancer Survivors.
Protocol: 132420Principal Investigator:
- Evelyn Arana
Applicable Disease Sites: Any Site -
Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination with Standard of Care for Newly Diagnosed Adult Glioblastoma
Protocol: 142501Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System -
Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination with Standard of Care for Newly Diagnosed Adult Glioblastoma
Protocol: 142501Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System